ISOLATION OF A STREPTOCOCCAL ANTIGEN AND ITS POSSIBLE 1627 ROLE IN THE PATHOGENESIS OF ACUTE POSTSTREPTOCOCCAL GLOMERULONEPHRITIS. Inge Sagel, Nobuyuki Yoshizawa, Gerhard Treser. Westchester County Medical Center, Departments of Pediatrics and Medicine, New York, New York. National Defense Medical College, Department of Medicine, Tokyo, Japan.

We studied the significance of a streptococcal protein (PA-Ag) in the pathogenesis of acute poststreptococcal glomerulonephritis (AGN). Purification of PA-Ag was achieved by chromatography fol-lowed by Sephadex isoelectric focusing. A single protein band at pH 4.7 was identified as PA-Ag. The molecular weight was 43000. Rabbit antisera against PA-Ag and sera of patients with AGN showed identical precipitation lines by immunodiffusion. Anti-bodies to PA-Ag determined by immunodiffusion were found to be present in 30 of 31 patients with AGN, in 1 of 36 patients with uncomplicated group A streptococcal upper respiratory tract in-fections and in 1 of 36 normal adults. These findings were con-firmed by the ELISA technique. Small doses of PA-Ag injected intravenously into rabbits produced glomerular changes similar to AGN with polymorphonuclear infiltration, cellular proliferation and staining for C3 by immunofluorescence. Control rabbits in-jected with BSA in similar doses did not develop glomerular Pathology. Following perfusion of PA-Ag into rabbit kidneys, PA-Ag was found to localize only on the glomerular basement mem-brane and in the mesangium. Using immunoelectrophoresis it was found that PA-Ag activates the alternate pathway of complement. Any other water soluble streptococcal fraction, used as control. did not activate the complement system. Our findings suggest that PA-Ag seems to be involved in the pathogenesis of AGN.

1628 CELLULAR GROWTH IN THE MATURING RABBIT KIDEY CORTICAL COLLECTING TUBULE (CCT). Lisa M. Satlin and George J. Schwartz, Albert Einstein College of Medicine, Dept. of Pediatrics, Div. of Nephrology, Bronx, New York. To stratal development of the proximal nephron is characterized by non-linear growth as a function of time (AJP 245;F391, 1983). We were imbryological origin differs from that of the proximal tubule. Mid-CTs from newborn (NB), 1 month old, and adult rabbits (n=4-7 animals per group) were isolated. Tubules (5-15 per animal) were measured for length and diameter, cell number (acridine orange), dry weight (quartz fiber balance) and K⁺ content (helium glow photometry). The number of cells/mm tubular length was similar in the NB and adult (534 ±34 and 551 ± 22). Cell growth was characterized by 50-60% increases (p<0.05) in volume (1105 ± 85 to 1633 ± 82 µm²/cell), dry weight (169 ± 15 to 260 ± 23 pg/cell), and K⁺ content (0.106 ± 0.011 to 0.164 ± 0.011 pmol/cell), with changes apparent only after 1 month of age. Cellular accretion of posteria and other solids was estimated to account for at least 90% of the observed weight gain. We calculated K⁺ content after the first month of file. The rise in K⁺/cell reflects primarily enhanced protein binding rather than addition of free cytosolic K⁺. The increase in CCT diameter (2.4 ± 0.5 to 33.9 ± 0.4 µm p < 0.05) results from cell hypertrophy. Since there was no change in the number of cells/mm tubular length, axial growth of the CCT (3-fold) must occur by hyperplasia, probably in the sperificial cortex. CCT growth may follow the postnatal surge in SNGFR and the opening of newly functioning superficial nephrons.

•1629 PRODUCTION OF THE LYMPHOKINE, SOLUBLE IMMUNE RESPONSE SUPPRESSOR (SIRS) BY PATIENTS WITH NEPHROTIC SYNDROME H. William Schnaper and Thomas M. Aune, (Spon. by Barbara R. Cole) Washington Univ. School of Medicine, Jewis Hospital of St. Louis.

Nephrotic patients often show suppressed immune responsiveness of unknown origin. At the last SPR meeting we reported that patients with active minimal change nephrotic syndrome (MCNS) or patients with active minimal change nephrotic syndrome (MCNS) or membranoproliferative glomerulonephritis (MPGN) excrete SIRS in their urine. This lymphokine, produced <u>in vitro</u> by interferon- or mitogen-activated suppressor T cells, inhibits division by normal and neoplastic cells and antibody secretion by B lymphocytes. SIRS activity disappears from urine after initiation of steroid therany but before remission of nephrosis. To determine whether SIKS activity disappears from urine after initiation of steroid therapy but before remission of nephrosis. To determine whether increased serum SIKS levels are also associated with these di-seases, sera from four patients (3MCNS, 1MPGN) were assayed for SIRS activity. Patient sera, but not control sera, suppressed immunoglobulin production by pokeweed mitogen-activated lympho-cytes by 55-70% at a final concentration of 2-10% in culture; Cycles by 55-70% at a final concentration of 2-10% in culture; suppressive activity was absorbed from serum by monoclonal anti-SIRS antibody. Lymphocytes obtained from two patients (IMCNS, IMPGN) produced SIRS without requiring activation by exogenous agents. These data suggest that lymphocytes of nephrotic pa-tients with MCNS or MPGN are continuously producing SIRS. This may account for the increased levels of SIRS (FIRS) and and and and and and a set of the increased levels of SIRS are set of the increased levels of SIRS (SIRS) and set of the increased levels of SIRS (SIRS) and set of the increased levels of SIRS (SIRS) and SIRS) and SIRS (SIRS) and SIRS (SIRS) are set of the increased levels of SIRS (SIRS) and SIRS) are set of the increased levels of SIRS (SIRS) and SIRS) are set of the increased levels of SIRS (SIRS) are set of the increased levels of SIRS) and SIRS (SIRS) are set of the increased levels of SIRS (SIRS) are set of the increased levels of SIRS) and SIRS (SIRS) are set of the increased levels of SIRS) are set of the increased levels of SIRS (SIRS) are set of the increased levels of SIRS) and SIRS (SIRS) are set of the increased levels of SIRS) are set of the increased levels of SIRS (SIRS) are set of the increased levels of SIRS) are set of the increased levels of SIRS (SIRS) are set of the increased levels of SIRS) are set of the increased levels of SIRS (SIRS) are set of the increased levels of SIRS) are set of the increased levels of SIRS (SIRS) are set of the increased levels of SIRS). There will may account for the increased levels of SIRS in sera and urine and may also account for immunosuppression in these patients. Finally, hydrocortisone $(10^{-6} \text{ to } 10^{-7}\text{M})$ inhibited production of SIRS by activated lymphocytes; this may explain cessation of SIRS excretion after initiation of steroid therapy.

THE NATURAL HISTORY OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE IN CHILDREN. <u>Aileen B. Sedman</u>, Michael L. Johnson, Robert C. Kelsch, Nancy Butler, 1630

Patricia A. Gabow. Univ Colo Health Sci Center, Univ Mich Med Center; Dept Ped and Med; Denver, CO, Ann Arbor, MI.

Polycystic kidney disease in children has often been called "infantile" on the basis of age alone; we sought to identify children <18 years of age with autosomal dominant polycystic kidney disease (APKD) documented by family workup. Twenty-for children were diagnosed by ultrasound as having APKD; 33 were Twenty-four suspicious for APKD (SAPKD) when unilateral, inhomogeneous or <5 cysts were seen. The 24 children with APKD were 9.3+6.4 yr. of age (x + 1 S.D.) with followup of 7.5+6.5 yr. (range $\overline{0}$ -29 yr.). of age $(x \pm 1 \text{ S.D.})$ with followup of 7.5±0.5 yr. (range 0-29 yr.). Sixty-two percent of APKD children had symptoms at presentation (abdominal pain, headaches, gross hematuria), 25% had hypertension (HTN), 20% had hernias, 12% had boney abnormalities. Forty-two percent had progression during followup (increased cysts, increased HTN, or decreased renal function). Twenty-one percent reached end-stage renal disease (ESRD) in 14.6±10.7 yr. percent reached end-stage renal disease (ESRD) in 14.6 ± 10.7 yr. (range 3-29 yr.). Four children had APKD diagnosed <1 year of age with followup 6.6\pm5.8 yr. Two reached ESRD: one at age 3, another at age 15 yr. The other two are stable at 1.5 and 5 yr. post-diagnosis. Thirty-three children with SAPKD (\bar{x} age 12.7 ± 3.4) had followup of 5.6 ±3.7 yr. Twenty percent had symptoms compatible with APKD, 77% progressed, 0% reached ESRD. Conclusions: There is wide variation in the oncet and Conclusions: There is wide variation in the onset and progression of APKD in childhood. Children with SAPKD may have prolonged stability but warrant meticulous followup. APKD in childhood is associated with other abnormalities.

1631 GLOMERULAR FILTRATION IN WEIGHT (VLBW) INFANTS NEUROMUSCULAR BLOCKING VERY LOW BIRTH TREATED WITH AGENT. <u>K.C.Sekar</u>, K.L.Harkavy, P.Jose. Dept. Pediatrics, Georgetown Univ., Washington D.C. (Spon. J.W. Scanlon). Pavulon (Pancuronium Bromide), although has little effect on the

circulatory system, not infrequently produces hypotension when administered to sick VLBW. We studied the glomerular filtration (GFR) by Inulin clearance and fractional sodium excretion (FeNa) in VLBW (n=5) by infinit clearance and fractional sodium excretion (FeNa) in VLBW (n=5) in the first 3 days of life receiving Pavulon (0.1 mg/kg/dose) and compared the results with a similar group (n=11) not receiving Pavulon. None were hypotensive or in renal failure. The IV fluid, sodium infusion and thermal environment did not differ between groups. Inulin was given with a bolus of 50 to 100 mg/kg followed by infusion of 0.1 to 0.2 mg/kg/min. Timed urine and serum were collected and clearances calculated in standard fashion. The results (mean + s.d.) are as follows:

			GFR(GFR(cc/kg/min)		FeNa	.%	
	GA	BW		Days		Day	s	
Group	(wks)	(Gms)	1	2	3	1	2	3
Pavulon	29 ±18	1060 ±165	0.124	0.369	0.396	1.45	2.49	3.36
(3,3,2)*			±0.07	±0.16	±0.20	+0.96	+2.8	+0.70
Control	28 ±2.3	3 958 ±152	0.329	0.367	0.475	1.37		
(8,6,9)*			±0.25	±0.14	±0.49	+1.4		
There were	e no si	gnificant	differe	nces	between	groups		ach day.
Payulon doos not offect CED on Eable is side WI DW								

Pavulon does not affect GFR or FeNa in sick VLBW infants. As a major portion of Pavulon is eliminated unchanged in urine, repeated administration in infants with renal failure may prolong its effect. (* indicates number of studies done on days 1,2, and 3.)

1632 THE ROLE OF PROSTAGLANDIN E2 (PGE2) IN A CONGENITAL HYPOKALEMIC TUBULAR DISORDER WITH HYPERCALCIURIA AND PREMATURITY. Hannsjörg W. Seyberth, Peter G. Kühl, Horst Schweer, Wolfgang Rascher, Karl Schärer. (Spons. by S.J. Yaffe). Univ. of Heidelberg, Children's Hospital, Heidelberg, Fed. Rep. of Germany.

A congenital subtype of hypokalemic tubular disorders in 5 children (age 8 m to 4 ys) is described with many features re-sembling Bartter's syndrome. Additional features are: Prenatal onset with polyhydramnios and premature labor; failure to thrive; life threatening crises of fever, diarrhea, renal electrolyte and water wasting (however with normal renal chloride reabsorption); hypercalciuria, nephrocalcinosis and osteopenia. Renal PGE₂ activity was monitored by mass spectrometric determination of urinary PGE₂, and systemic PGE₂ activity by a major urinary metabolite (PGE-M). The pathogenetic role of PGE₂ is supported by withdrawal of PG synthesis inhibitors (PGSI) indomethacin or aspirin.

-			-
	PRE	PGSI with- drawal (3d)	POST (2-4m)
K (serum) mmol/1	3.8(3.2-5.1)	2.2(2.1-2.8)*	4.0(3.3-4.1)
Ca (urine) mg/kg/d	6.4(1.9-11.7)	13.0(2.4-14.5)*	7.3(2.3-8.2)
Urine ml/min/1.73m ²	1.8(0.8-2.9)	2.8(0.9-3.6)*	1.3(0.7-1.9)
PGE ₂ ng/h/1.73m ²	6(0-51)	65(25-102)*	7(2-17)
PGE-M μg/h/1.73m ²	0.1(0.1-1.9)	1.7(0.8-3.4)*	0.1(0.1-0.2)
median (range) *od	1(n=5) norm	al PGE · 2-16 PGE	E-M· 0 1-0 7

dian (range) *p<0.1(n=5). normal PGE₂: 2-16, PGE-M: 0.1-0.7 Prolonged indomethacin treatment significantly improved the affected children's general condition. We conclude that renal as well as systemic PGE₂ hyperactivity ranks high in the pathogenetic chain of events in this complex tubular disorder.

382A